In primary AML samples at diagnosis, we observed that samples with IC50 values to Ara-C, Dnr, and ATO above the median had high NRF2 mRNA expression compared to those below the median suggesting that Nrf2 is aberrantly expressed in resistant AML samples. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.